How has Protagonist Therapeutics's change in deferred revenue changed year-over-year?

Protagonist Therapeutics's change in deferred revenue increased by 40.5% year-over-year, from -$5.5M to -$3.27M.

What does change in deferred revenue mean?

Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.

Protagonist Therapeutics PTGX Change in Deferred Revenue

Change in Deferred Revenue at other companies

Regeneron PharmaceuticalsREGN

$99.6M+463%

Arrowhead ResearchARWR

$163.36M—

Kymera TherapeuticsKYMR

——

PTC TherapeuticsPTCT

——

Rhythm Pharmaceuticals, Inc.RYTM

——

Other financials

Income statement

See full

Revenue$56.4M+99.0%

Operating income-$3.6M+81.1%

Net income$3.8M+132%

EPS (diluted)$0.05+126%

Balance sheet

See full

Cash & equivalents$193.7M+38.7%

Total debt$9.8M-13.9%

Total equity$655.5M-4.9%

Total assets$697.5M-6.0%

Cash flow

See full

Operating cash flow-$48.9M-139%

CapEx$215.0K-60.6%

Free cash flow-$49.2M-139%

Valuation

See full

Market cap$7.26B+127%

Enterprise value$7.07B+130%

P/S98×+82.6×

Profitability

See full

Operating margin-192.4%-205pp

Net margin-154.9%-182pp

FCF margin-12,264.3%-12,527pp

Returns & leverage

See full

Return on equity-17.1%-26.1pp

Debt / equity0×0.0×

Current ratio17.8×+0.5×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Protagonist Therapeutics's change in deferred revenue?: Protagonist Therapeutics (PTGX) reported change in deferred revenue of -$3.27M in Q1 2026.
How has Protagonist Therapeutics's change in deferred revenue changed year-over-year?: Protagonist Therapeutics's change in deferred revenue increased by 40.5% year-over-year, from -$5.5M to -$3.27M.
What does change in deferred revenue mean?: Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.